Cbl-b-IN-29

Cbl-b-IN-29 is an orally active CBL-B inhibitor. Cbl-b-IN-29 binds to the CBL-B active pocket. Cbl-b-IN-29 induces Jurkat cell release IL-2 with an EC50 of 159 nM, effectively inhibiting the function of immune E3 ubiquitin ligase. Cbl-b-IN-29 demonstrates robust anti-tumor efficacy in vivo with good tolerability and no observed adverse reactions. Cbl-b-IN-29 can be used for cancer immunotherapy, colorectal cancer and immune-oncology combination research[1].

Product Specifications

CAS Number

3070411-10-5

UNSPSC

12352005

Target

E1/E2/E3 Enzyme; Interleukin Related

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease

Field of Research

Cancer; Inflammation/Immunology

Smiles

CN1C([C@]2(C[C@@H](C)C2)C3=CC(C4=CC5=C(C([C@@H](C)NC6CCCC6)=CC=C5F)NC4=O)=CC=C3)=NN=C1

Molecular Formula

C30H34FN5O

Molecular Weight

499.62

References & Citations

[1]Han Wang, et al. A unified language model bridging de novo and fragment-based 3D molecule design delivers potent CBL-B inhibitors for cancer treatment. bioRxiv, 2025.11.13.688260